A recent study evaluated how a new serum called REVIVV®, formulated using a proprietary blend of plant extracts and bioactives, could help patients with androgenetic alopecia (AGA) improve their quality of life and emotional wellbeing.
Researchers from New York, New Jersey, and South Africa conducted this observational, real-world study from January 2022 to June 2022 with 150 ethnically diverse men and women aged 38-75 years.
For four weeks prior to the study, participants were instructed not to use any hair treatments that could affect hair loss and to also discontinue the use of antihistamines, anti-inflammatories, immunosuppressive therapies, and retinoids.
Participants used a roller to apply REVIVV to the frontal, crown, and vertex areas of the scalp in a circular motion and left it on overnight. Formulations differed slightly for men and women. It was revealed that the use of REVIVV twice daily resulted in improved hair growth, which was reported by both participant self-assessment and clinical corroboration.
At the eight-week mark following baseline, none of the participants in the study reported any discomfort, with 80% reporting improvement in hair growth, hair volume, scalp coverage, and amount of hair regrowth. All of the participants also reported that the product was easy to use and they saw a decrease in hair shedding. Most of the participants stated they would continue to use the product after the end of the study.
REVIVV is formulated with green tea extract, extracts rich in flavonoids, menthol, and caffeine, as well as other plant ingredients known to possess pleiotropic anti-inflammatory, antioxidant, antimicrobial, and anti-androgen properties.
According to the study authors, “The positive outcome from topical application of select extracts and isolates can therefore improve the physiology of hair follicles and scalp skin by modulation of proinflammatory cytokines, improvement of redox balance in cells, and a decrease of local steroidogenesis (DHT and cortisol formulation).”
They add that treatments “need to be designed accordingly, not as monotherapies but rather with the goal of formulating a multi-prong approach, targeting all the etiological factors to stop and reverse AGA, then restore hair follicle homeostastis.”
